Cancer and fungal disease demand, safer targeted therapies, patent-driven reformulations and Asia-Pacific expansion create opportunities as cubosomes, AI and continuous manufacturing gain traction.
Liposome Drug Delivery Market Estimated Number Of New Cancer Cases In Million By Region 2020 2040
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) — The “Liposome Drug Delivery – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” has been added to ResearchAndMarkets.com’s offering.
Liposome Drug Delivery Market to Reach USD 9.48 Billion by 2031 as Oncology Demand Accelerates
The global liposome drug delivery market is estimated to reach USD 6.39 billion in 2026, rising from USD 5.91 billion in 2025. The market is forecast to expand at a compound annual growth rate of 8.19% between 2026 and 2031, reaching USD 9.48 billion by the end of the forecast period. Growth is being supported by increasing cancer incidence, demand for safer pharmaceutical formulations, advances in targeted drug delivery, and continued adoption of liposomal therapies for fungal infections.
Global Liposome Drug Delivery Market Trends and Growth Drivers
Cancer therapeutics remain a primary growth engine for the liposome drug delivery market. Targeted liposomal formulations can concentrate chemotherapy at tumor sites while reducing systemic toxicity. PEGylated liposomal doxorubicin, for example, can remain in circulation for approximately 55 hours, compared with less than 10 minutes for free doxorubicin. This extended circulation profile supports sustained clinical demand across ovarian cancer, multiple myeloma, and other oncology indications.
Rising rates of fungal infections among immunocompromised patients are also increasing the use of liposomal amphotericin B. The formulation maintains antifungal activity while lowering nephrotoxicity, strengthening its role in treating severe and invasive infections. Together, cancer and fungal infections provide a durable foundation for market expansion and pharmaceutical pipeline investment.
A growing body of clinical evidence supporting improved safety, lower severe toxicity, and longer survival is encouraging the adoption of liposomal medicines. The U.S. Food and Drug Administration’s 2024 decision involving irinotecan liposome highlighted this benefit-risk profile, with median overall survival reaching 11.1 months compared with 9.2 months for standard therapy. Positive clinical outcomes are helping liposomal formulations gain earlier placement in treatment pathways.
Market growth is moderated by stringent chemistry, manufacturing, and controls requirements. Regulators require detailed particle-size, encapsulation, and release-profile data, while aseptic processing adds manufacturing complexity and cost. Smaller pharmaceutical companies may lack the analytical infrastructure and Good Manufacturing Practice facilities required for compliance, favoring established manufacturers with advanced production capabilities.
Additional market influences include the rapid adoption of PEGylation and stealth technologies, patent expirations that encourage liposomal reformulation programs, and concerns surrounding anti-PEG antibody-related hypersensitivity events.
Product and Technology Insights
Liposomal doxorubicin generated USD 2.12 billion in 2025, accounting for 35.92% of total market revenue. Its established record of reduced cardiotoxicity continues to support adoption, while hyperthermia-triggered variants are being developed to increase localized drug release without significantly changing systemic exposure.
Liposomal paclitaxel is projected to record a strong 11.09% CAGR as oncology centers adopt formulations designed to avoid Cremophor-associated hypersensitivity. Liposomal amphotericin B continues to serve stable infectious-disease demand, while irinotecan liposome is gaining attention as a first-line option for metastatic pancreatic cancer. Pipeline programs are also evaluating temperature-sensitive vesicles capable of delivering cytotoxic therapies with high encapsulation and controlled release.
PEGylated stealth technologies represented 60.65% of market revenue in 2025, supported by established safety data and well-characterized manufacturing methods. However, hypersensitivity concerns are prompting research into ganglioside and zwitterionic alternatives. Cubosome-based lipid nanoparticles are forecast to advance at a 10.42% CAGR, driven by their potential in endosomal escape and gene-editing payload delivery.
DepoFoam multivesicular technology continues to demonstrate value in controlled-release pain management, including bupivacaine delivery lasting up to 96 hours. Continuous-flow manufacturing and artificial intelligence-assisted lipid ratio selection are also emerging as tools to reduce production costs and batch variability.
Regional Liposome Drug Delivery Market Outlook
North America accounted for 40.78% of global revenue in 2025. The region benefits from established reimbursement pathways, extensive clinical trial networks, predictable regulatory processes, and investment in domestic continuous-manufacturing facilities. These conditions support premium pricing when manufacturers demonstrate reduced toxicity or improved survival.
Europe maintains strong adoption through centralized regulatory procedures and specialist oncology networks in Germany, France, and the United Kingdom. Horizon Europe grants supporting lipid nanoparticle vaccines and more resilient supply chains are expected to encourage further innovation and commercialization.
Asia-Pacific is forecast to post the fastest regional CAGR of 10.57% through 2031. China’s contract development and manufacturing organizations are expanding cost-efficient GMP production, while Singapore and South Korea continue investing in advanced therapy manufacturing. High rates of stomach, liver, and lung cancers, broader insurance coverage, and growing demand for generic liposomal oncology drugs are strengthening the region’s outlook.
Latin America and the Middle East and Africa are expected to experience more gradual adoption because of reimbursement limitations and cold-chain constraints. Nevertheless, oncology center investments in Gulf Cooperation Council countries, continuous-flow manufacturing initiatives in Brazil, and clinical research into inhalable liposomal tuberculosis therapies in South Africa are creating new growth opportunities.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence Of Cancer & Fungal Infections
4.2.2 Proven Safety-Bias Vs. Conventional Formulations
4.2.3 Rapid Adoption Of Pegylation & Stealth Technologies
4.2.4 Expiring Patents Pushing Liposomal Reformulations
4.2.5 Cubosome & Other Non-Spherical LNPs Boosting Uptake
4.2.6 AI/ML-Guided Lipid Composition Optimisation
4.3 Market Restraints
4.3.1 Stringent CMC / Sterility Regulations
4.3.2 High Manufacturing CAPEX & Scale-Up Complexity
4.3.3 Short Shelf-Life & Cold-Chain Dependence
4.3.4 Anti-PEG Antibody-Driven Hypersensitivity Events
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technology Outlook
4.7 Porter’s Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Product
5.1.1 Liposomal Paclitaxel
5.1.2 Liposomal Doxorubicin
5.1.3 Liposomal Amphotericin B
5.1.4 Vyxeos (Daunorubicin + Cytarabine)
5.1.5 Liposomal Irinotecan
5.1.6 Others
5.2 By Technology
5.2.1 PEGylated (Stealth)
5.2.2 Non-PEGylated Conventional
5.2.3 DepoFoam
5.2.4 Cubosome-based LNPs
5.3 By Indication
5.3.1 Cancer Therapeutics
5.3.2 Fungal Infections
5.3.3 Pain Management
5.3.4 Viral Vaccines
5.3.5 CNS Disorders
5.4 By Route of Administration
5.4.1 Intravenous
5.4.2 Intrathecal / Intraventricular
5.4.3 Topical / Dermal
5.4.4 Ocular
5.4.5 Pulmonary / Inhalation
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Gilead Sciences
6.3.2 Pacira BioSciences
6.3.3 Spectrum Pharmaceuticals
6.3.4 Takeda Pharma
6.3.5 Luye Pharma
6.3.6 Johnson & Johnson
6.3.7 Ipsen Pharma
6.3.8 Celsion Corporation
6.3.9 Teva Pharmaceutical
6.3.10 Novartis AG
6.3.11 Sun Pharma
6.3.12 Acrotech Biopharma
6.3.13 Bristol Myers Squibb
6.3.14 Pfizer Inc.
6.3.15 Merck KGaA
6.3.16 Astellas Pharma
6.3.17 Acuitas Therapeutics
6.3.18 Arcturus Therapeutics
6.3.19 Evonik Health Care
6.3.20 NanoCarrier Co.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/8crpub
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Liposome Drug Delivery Market Estimated Number Of New Cancer Cases In Million By Region 2020 2040
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
